Results 131 to 140 of about 278,227 (245)

Patient expectations of surgery outcomes for appearance-altering eye conditions [PDF]

, 2016
Conditions affecting the eyes can be associated with impaired vision, social functioning and reduced quality of life. Unsurprisingly, patients with these problems often seek surgery to improve their vision and change their appearance. Elizabeth Jenkinson
Jenkinson, E., Wickwar, S.
core   +1 more source

A pilot study on the use of prednisolone‐encapsulated liposomes for the treatment of moderate‐to‐severe Graves’ orbitopathy with reduced systemic steroid exposure [PDF]

, 2021
Sanne E. Detiger, Tessa M. Kremer, Virgil A. S. H. Dalm, Ronald O. B. de Keizer, René J. Wubbels, Josbert M. Metselaar, P. Martin van Hagen, Robin P. Peeters, Dion Paridaens   +8 more
openalex   +1 more source

Selenium improves mild Graves’Orbitopathy: a randomized, double-blind, placebo-controlled study. [PDF]

, 2011
Background Free oxygen radicals and cytokines play a pathogenic role in Graves’ orbitopathy (GO). This study reports the results of a randomized, double-blind, placebo-controlled trial on the effect of selenium, an antioxidant agent, or pentoxifylline ...
ALTEA, MARIA ANTONIETTA
core  

Functional and Morphological Changes in the Visual Pathway in Patients with Graves’ Orbitopathy [PDF]

, 2022
Agnieszka Jagiełło-Korzeniowska, Agata Bałdys‐Waligórska, Alicja Hubalewska‐Dydejczyk, Bożena Romanowska‐Dixon   +3 more
openalex   +1 more source

Serum concentrations of HGF and IL-8 in patients with active Graves’ orbitopathy before and after methylprednisolone therapy [PDF]

, 2015
Mariusz Nowak, Lucyna Siemińśka, Jacek Karpe, Bogdan Marek, Beata Kos‐Kudła, Dariusz Kajdaniuk   +5 more
openalex   +1 more source

Endoscopic transnasal orbital decompression for thyrotoxic orbitopathy [PDF]

, 2002
Objective. To evaluate the efficacy of endoscopic transnasal orbital decompression alone for thyrotoxic orbitopathy. Design. Retrospective review of consecutive procedures. Setting. Tertiary referral otorhinolaryngology centre. Patients.
Chan, E, Kung, AWC, Kwan, KYW, Lam, KSL, Yuen, APW   +4 more
core  

TSH-receptor antibodies may prevent bone loss in pre- and postmenopausal women with Graves' disease and Graves' orbitopathy

Archives of Endocrinology and Metabolism
Objective Thyrotoxicosis is established risk factor for osteoporosis due to increased bone turnover. Glucocorticoids often administered for Graves' orbitopathy (GO) have additional negative effect on bone mineral density (BMD). Our aim was to examine the
Mira Siderova, Kiril Hristozov, Aleksandra Tsukeva   +2 more
doaj   +1 more source

Graves’ orbitopathy after allogeneic bone marrow transplantation in a patient with Fanconi anemia – side effect of alemtuzumab therapy?

Clinical Case Reports, 2018
Key Clinical Message A few cases of thyroid eye disease following alemtuzumab therapy have been described in patients with multiple sclerosis. Our patient is the first case of Graves’ orbitopathy after alemtuzumab conditioning for hematopoietic stem cell
Luminita Nicoleta Cima, Ioana Maria Lambrescu, Lavinia Stejereanu, Anca Colita, Reuven Or, Simona Fica   +5 more
doaj   +1 more source

Evaluation of Quality of Life in the Brazilian Graves' Disease Population: Focus on Mild and Moderate Graves' Orbitopathy Patients

Frontiers in Endocrinology, 2019
Background: Quality of life (QoL) studies in patients with mild to moderate Graves' orbitopathy (GO) are scarce.Methods: The original GO-QoL questionnaire was translated to Portuguese and administered to 323 patients with Graves' disease.
Danilo Villagelin, Danilo Villagelin, João Romaldini, João Romaldini, Juliana Andrade, Roberto Santos, Ana Milkos, Patricia Fátima dos Santos Teixeira, Laura S. Ward   +8 more
doaj   +1 more source

Efficacy and safety of low dose oral prednisolone as compared to pulse intravenous methylprednisolone in managing moderate severe Graves′ orbitopathy: A randomized controlled trial

Indian Journal of Endocrinology and Metabolism, 2015
Background: High dose oral prednisolone (100 mg/day) in Graves′ orbitopathy (GO) is limited by lesser response, and greater side-effects compared to intravenous (iv) methylprednisolone. Low dose oral prednisolone has not been evaluated in GO.
Ajitesh Roy, Deep Dutta, Sujoy Ghosh, Pradip Mukhopadhyay, Satinath Mukhopadhyay, Subhankar Chowdhury   +5 more
doaj   +1 more source